{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T07:14:07Z","timestamp":1775805247336,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T00:00:00Z","timestamp":1613174400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,13]],"date-time":"2021-02-13T00:00:00Z","timestamp":1613174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"JSPS KAKENHI grant","award":["16K10269"],"award-info":[{"award-number":["16K10269"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s12149-021-01597-5","type":"journal-article","created":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T08:42:49Z","timestamp":1613292169000},"page":"514-522","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Potential of three-step pretargeting radioimmunotherapy using biotinylated bevacizumab and succinylated streptavidin in triple-negative breast cancer xenograft"],"prefix":"10.1007","volume":"35","author":[{"given":"Wenchao","family":"Gu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Yudistiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2421-7397","authenticated-orcid":false,"given":"Hirofumi","family":"Hanaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsumi","family":"Katsumata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshito","family":"Tsushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,13]]},"reference":[{"key":"1597_CR1","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.ijrobp.2004.02.065","volume":"59","author":"MC Hernandez","year":"2004","unstructured":"Hernandez MC, Knox SJ. Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin\u2019s lymphoma. Int J Radiat Oncol. 2004;59:1274\u201387.","journal-title":"Int J Radiat Oncol"},{"key":"1597_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11523-014-0324-y","volume":"10","author":"ED Read","year":"2015","unstructured":"Read ED, Eu P, Little PJ, Piva TJ. The status of radioimmunotherapy in CD20+ non-Hodgkin\u2019s lymphoma. Target Oncol. 2015;10:15\u201326.","journal-title":"Target Oncol"},{"key":"1597_CR3","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/psp4.12224","volume":"6","author":"JT Ryman","year":"2017","unstructured":"Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol. 2017;6:576\u201388.","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"key":"1597_CR4","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.nucmedbio.2007.04.001","volume":"34","author":"CA Boswell","year":"2007","unstructured":"Boswell CA, Brechbiel MW. Development of radioimmunotherapeutic and diagnostic antibodies: an inside-out view. Nucl Med Biol. 2007;34:757\u201378.","journal-title":"Nucl Med Biol"},{"key":"1597_CR5","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/nbt1142","volume":"23","author":"P Holliger","year":"2005","unstructured":"Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol. 2005;23:1126\u201336.","journal-title":"Nat Biotechnol"},{"key":"1597_CR6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nrc3925","volume":"15","author":"SM Larson","year":"2015","unstructured":"Larson SM, Carrasquillo JA, Cheung NKV, Press OW. Radioimmunotherapy of human tumours. Nat Rev Cancer. 2015;15:347\u201360.","journal-title":"Nat Rev Cancer."},{"key":"1597_CR7","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1158\/1078-0432.CCR-06-2436","volume":"13","author":"M Jain","year":"2007","unstructured":"Jain M, Venkatraman G, Batra SK. Optimization of radioimmunotherapy of solid tumors: biological impediments and their modulation. Clin Cancer Res. 2007;13:1374\u201382.","journal-title":"Clin Cancer Res"},{"key":"1597_CR8","doi-asserted-by":"publisher","first-page":"7373","DOI":"10.1158\/1078-0432.CCR-11-1204","volume":"17","author":"SI Park","year":"2011","unstructured":"Park SI, Shenoi J, Frayo SM, Hamlin DK, Lin Y, Wilbur DS, et al. Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-Hodgkin lymphoma. Clin Cancer Res. 2011;17:7373\u201382.","journal-title":"Clin Cancer Res"},{"key":"1597_CR9","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/BF00448541","volume":"9","author":"D Goodwin","year":"1984","unstructured":"Goodwin D, Meares C, Diamanti C, McCall M, Lai C, Torti F, et al. Use of specific antibody for rapid clearance of circulating blood background from radiolabeled tumor imaging proteins. Eur J Nucl Med. 1984;9:209\u201315.","journal-title":"Eur J Nucl Med"},{"key":"1597_CR10","first-page":"987","volume":"8","author":"Group NP","year":"2001","unstructured":"Group NP. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nature Med. 2001;8:987\u20139.","journal-title":"Nature Med"},{"key":"1597_CR11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1158\/0008-5472.671.65.3","volume":"65","author":"HP Gerber","year":"2005","unstructured":"Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 2005;65:671\u201380.","journal-title":"Cancer Res"},{"key":"1597_CR12","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nrc3627","volume":"13","author":"HL Goel","year":"2013","unstructured":"Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer. 2013;13:871\u201382.","journal-title":"Nat Rev Cancer"},{"key":"1597_CR13","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.2967\/jnumed.107.041301","volume":"48","author":"WB Nagengast","year":"2007","unstructured":"Nagengast WB, De Vries EG, Hospers GA, Mulder NH, de Jong JR, Hollema H, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med. 2007;48:1313\u20139.","journal-title":"J Nucl Med"},{"key":"1597_CR14","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.2967\/jnumed.112.117218","volume":"54","author":"SBM Gaykema","year":"2013","unstructured":"Gaykema SBM, Brouwers AH, Lub-de Hooge MN, Pleijhuis RG, Timmer-Bosscha H, Pot L, et al. 89Zr-bevacizumab PET imaging in primary breast cancer. J Nucl Med. 2013;54:1014\u20138.","journal-title":"J Nucl Med"},{"key":"1597_CR15","first-page":"371","volume":"288","author":"YS Lin","year":"1999","unstructured":"Lin YS, Nguyen C, Mendoza JL, Escandon E, Fei D, Meng YG, et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther. 1999;288:371\u20138.","journal-title":"J Pharmacol Exp Ther"},{"key":"1597_CR16","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1200\/JCO.2001.19.3.843","volume":"19","author":"MS Gordon","year":"2001","unstructured":"Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001;19:843\u201350.","journal-title":"J Clin Oncol"},{"key":"1597_CR17","first-page":"3873s","volume":"9","author":"S Lindegren","year":"2003","unstructured":"Lindegren S, Karlsson B, Jacobsson L, Andersson H, Hultborn R, Skarnemark G. 211At-labeled and biotinylated effector molecules for pretargeted radioimmunotherapy using poly-L-and poly-D-lysine as multicarriers. Clin Cancer Res. 2003;9:3873s-s3879.","journal-title":"Clin Cancer Res"},{"key":"1597_CR18","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1021\/bc015574n","volume":"13","author":"DS Wilbur","year":"2002","unstructured":"Wilbur DS, Hamlin DK, Meyer DL, Mallett RW, Quinn J, Vessella RL, et al. Streptavidin in antibody pretargeting. 3. Comparison of biotin binding and tissue localization of 1,2-cyclohexanedione and succinic anhydride modified recombinant streptavidin. Bioconjug Chem. 2002;13:611\u201320.","journal-title":"Bioconjug Chem."},{"key":"1597_CR19","doi-asserted-by":"publisher","first-page":"14325","DOI":"10.1073\/pnas.1518808112","volume":"112","author":"SM Tolaney","year":"2015","unstructured":"Tolaney SM, Boucher Y, Duda DG, Martin JD, Seano G, Ancukiewicz M, et al. Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. Proc Natl Acad Sci U S A. 2015;112:14325\u201330.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1597_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2147\/BCTT.S69488","volume":"8","author":"G Jerusalem","year":"2016","unstructured":"Jerusalem G, Lousberg L, Schroeder H, Collignon J. Triplenegative breast cancer: treatment challenges and solutions. Breast Cancer Targets Ther. 2016;8:93\u2013107.","journal-title":"Breast Cancer Targets Ther"},{"key":"1597_CR21","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1021\/acs.molpharmaceut.8b00027","volume":"15","author":"R Yudistiro","year":"2018","unstructured":"Yudistiro R, Hanaoka H, Katsumata N, Yamaguchi A, Tsushima Y. Bevacizumab Radioimmunotherapy (RIT) with accelerated blood clearance using the avidin chase. Mol Pharm. 2018;15:2165\u201373.","journal-title":"Mol Pharm"},{"key":"1597_CR22","first-page":"750","volume":"26","author":"H Sakahara","year":"1985","unstructured":"Sakahara H, Endo K, Nakashima T, Koizumi M, Ohta H, Torizuka K, et al. Effect of DTPA conjugation on the antigen binding activity and biodistribution of monoclonal antibodies against alpha-Fetoprotein. J Nucl Med. 1985;26:750\u20135.","journal-title":"J Nucl Med"},{"key":"1597_CR23","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1038\/ki.1995.188","volume":"47","author":"B Schechter","year":"1995","unstructured":"Schechter B, Arnon R, Colas C, Burakova T, Wilchek M. Renal accumulation of streptavidin: Potential use for targeted therapy to the kidney. Kidney Int. 1995;47:1327\u201335.","journal-title":"Kidney Int"},{"key":"1597_CR24","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/j.1432-1033.1990.tb15493.x","volume":"189","author":"B Schechter","year":"1990","unstructured":"Schechter B, Silberman R, Arnon R, Wilchek M. Tissue distribution of avidin and streptavidin injected to mice: Effect of avidin carbohydrate, streptavidin truncation and exogenous biotin. Eur J Biochem. 1990;189:327\u201331.","journal-title":"Eur J Biochem"},{"key":"1597_CR25","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1021\/bc0000987","volume":"12","author":"SW Tsai","year":"2001","unstructured":"Tsai SW, Li L, Williams LE, Anderson AL, Raubitschek AA, Shively JE. Metabolism and renal clearance of 111In-labeled DOTA-conjugated antibody fragments. Bioconjug Chem. 2001;12:264\u201370.","journal-title":"Bioconjug Chem"},{"key":"1597_CR26","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s00259-010-1685-9","volume":"38","author":"E Vegt","year":"2011","unstructured":"Vegt E, Melis M, Eek A, de Visser M, Borm M, Oyen WJG, et al. Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice. Eur J Nucl Med Mol Imaging. 2011;38:623\u201332.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1597_CR27","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1021\/bc970182v","volume":"9","author":"DS Wilbur","year":"1998","unstructured":"Wilbur DS, Hamlin DK, Buhler KR, Pathare PM, Vessella RL, Stayton PS, et al. Streptavidin in antibody pretargeting 2 Evaluation of methods for decreasing localization of streptavidin to kidney while retaining its tumor binding capacity. Bioconjug Chem. 1998;9:322\u201330.","journal-title":"Bioconjug Chem."},{"key":"1597_CR28","first-page":"140","volume":"47","author":"GJ F\u00f6rster","year":"2006","unstructured":"F\u00f6rster GJ, Santos EB, Smith-Jones PM, Zanzonico P, Larson SM. Pretargeted radioimmunotherapy with a single-chain antibody\/streptavidin construct and radiolabeled DOTA-biotin: Strategies for reduction of the renal dose. J Nucl Med. 2006;47:140\u20139.","journal-title":"J Nucl Med"},{"key":"1597_CR29","doi-asserted-by":"crossref","unstructured":"Cremonesi M, Ferrari M, Grana CM, Vanazzi A, StabinM, Bartolomei M, et al. High-dose radioimmunotherapy with 90Y-ibritumomab tiuxetan: comparative dosimetric study for tailored treatment. J Nucl Med. 2007;48:1871\u22129.","DOI":"10.2967\/jnumed.107.044016"},{"key":"1597_CR30","first-page":"4611","volume":"55","author":"LT Baxter","year":"1995","unstructured":"Baxter LT, Zhu H, Mackensen DG, Butler WF, Jain RK. Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res. 1995;55:4611\u201322.","journal-title":"Cancer Res"},{"key":"1597_CR31","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s002620050492","volume":"46","author":"N Oriuchi","year":"1998","unstructured":"Oriuchi N, Watanabe N, Kanda H, Hashimoto M, Sugiyama S, Takenoshita S, et al. Antibody-dependent difference in biodistribution of monoclonal antibodies in animal models and humans. Cancer Immunol Immunother. 1998;46:311\u20137.","journal-title":"Cancer Immunol Immunother"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-021-01597-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12149-021-01597-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-021-01597-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T04:34:30Z","timestamp":1671251670000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12149-021-01597-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,13]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1597"],"URL":"https:\/\/doi.org\/10.1007\/s12149-021-01597-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-93283\/v1","asserted-by":"object"}]},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,13]]},"assertion":[{"value":"30 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}